Eidos Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | |
|---|---|---|---|
| Revenue | $26.7M | — | — |
| Operating income | −$12.6M | −$8.0M | −$12.0M |
| Net income | −$37.8M | −$40.7M | −$11.9M |
| Total assets | $203.8M | $160.1M | $6.3M |
| Total liabilities | $32.4M | $5.1M | $2.5M |
| Equity | $171.4M | $155.0M | −$13.2M |
| EPS (diluted) | $-0.32 | — | — |
| Shares out. | 36.8M | 36.8M | 5.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −47.1%
- Net margin
- −141.8%
- Return on equity
- −22.1%
- Return on assets
- −18.6%
- Return on capital (ROCE)
- −6.5%
- Liabilities / assets
- 15.9%
- Debt / equity
- 0.19×
- Book value / share
- $4.66
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- 9.46safe
- Accruals / assets
- −3.0%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 3 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2019
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2027-07Open-Label Study of AG10 in Patients with Cardiomyopathy
- Phase 3Active Not Recruitingreadout ~2028-04-15Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
- Phase 3Recruitingreadout ~2031-10Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Phase 3Not Yet Recruitingreadout ~2037-11To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · New financial obligation · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJan 26, 2021
- Shareholder vote · Other material eventJan 20, 2021
- Other material eventJan 12, 2021
- Results of operationsOct 29, 2020
- Entered a material agreementOct 7, 2020
- Other material eventOct 5, 2020
- Regulation FD disclosureSep 29, 2020
- Director / officer change · Regulation FD disclosure · Other material eventAug 7, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BFeb 5, 2021
- 4FORM 4 SUBMISSIONJan 28, 2021
- 4FORM 4 SUBMISSIONJan 28, 2021
- 4FORM 4 SUBMISSIONJan 28, 2021
- 4FORM 4 SUBMISSIONJan 28, 2021
- 4FORM 4 SUBMISSIONJan 28, 2021
- 4FORM 4 SUBMISSIONJan 28, 2021
- 4FORM 4 SUBMISSIONJan 28, 2021
- 4FORM 4 SUBMISSIONJan 28, 2021
- EFFECTJan 27, 2021
- SC 13D/ASC 13D/A #1Jan 26, 2021
- S-8 POSJan 26, 2021
- S-8 POSJan 26, 2021
- S-8 POSJan 26, 2021
- POS AMJan 26, 2021
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.